. 2015; 32(4): 323-328 | DOI: 10.4274/Tjh.2014.0152 | |||
Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey ExperienceFüsun Özdemirkıran1, Bahriye Payzın1, H. Demet Kiper2, Sibel Kabukçu3, Gülsüm Akgün Çağlıyan4, Selda Kahraman5, Ömür Gökmen Sevindik6, Cengiz Ceylan7, Gürhan Kadıköylü8, Fahri Şahin2, Ali Keskin3, Öykü Arslan4, Mehmet Ali Özcan6, Gülnur Görgün7, Zahit Bolaman8, Filiz Büyükkeçeci2, Oktay Bilgir4, İnci Alacacıoğlu6, Filiz Vural2, Murat Tombuloğlu, Zafer Gökgöz, Güray Saydam21Katip Çelebi University Faculty of Medicine, Atatürk Research and Education Hospital, Clinic of Hematology, İzmir, Turkey2Ege University Faculty of Medicine, Department of Hematology, İzmir, Turkey 3Pamukkale University Faculty of Medicine, Department of Hematology, Denizli, Turkey 4Bozyaka Research and Education Hospital, Clinic of Hematology, İzmir, Turkey 5Aydın State Hospital, Clinic of Hematology, Aydın, Turkey 6Dokuz Eylül University Faculty of Medicine, Department of Hematology, İzmir, Turkey 7Tepecik Research and Education Hospital, Clinic of Hematology, İzmir, Turkey 8Adnan Menderes University Faculty of Medicine, Department of Hematology, Aydın, Turkey INTRODUCTION: OBJECTIVE: Immune thrombocytopenia (ITP) is an immune mediated disease characterized by transient or persistent decrease of the platelet count to less than 100 × 109/l. Although it is included in a benign disease group, bleeding complications may be mortal. With a better understanding of the pathophysiology of the disease, thrombopoietin receptor agonists which came into use in recent years, seem to be an effective option in the treatment of resistant patients. İmmün Trombositopeni Tedavisinde Eltrombopag: Türkiye Ege Bölgesi DeneyimiFüsun Özdemirkıran1, Bahriye Payzın1, H. Demet Kiper2, Sibel Kabukçu3, Gülsüm Akgün Çağlıyan4, Selda Kahraman5, Ömür Gökmen Sevindik6, Cengiz Ceylan7, Gürhan Kadıköylü8, Fahri Şahin2, Ali Keskin3, Öykü Arslan4, Mehmet Ali Özcan6, Gülnur Görgün7, Zahit Bolaman8, Filiz Büyükkeçeci2, Oktay Bilgir4, İnci Alacacıoğlu6, Filiz Vural2, Murat Tombuloğlu, Zafer Gökgöz, Güray Saydam21Katip Çelebi University Faculty of Medicine, Atatürk Research and Education Hospital, Clinic of Hematology, İzmir, Turkey2Ege University Faculty of Medicine, Department of Hematology, İzmir, Turkey 3Pamukkale University Faculty of Medicine, Department of Hematology, Denizli, Turkey 4Bozyaka Research and Education Hospital, Clinic of Hematology, İzmir, Turkey 5Aydın State Hospital, Clinic of Hematology, Aydın, Turkey 6Dokuz Eylül University Faculty of Medicine, Department of Hematology, İzmir, Turkey 7Tepecik Research and Education Hospital, Clinic of Hematology, İzmir, Turkey 8Adnan Menderes University Faculty of Medicine, Department of Hematology, Aydın, Turkey GİRİŞ ve AMAÇ: İmmün trombositopeni (İTP), trombositlerin immün aracılı yıkım ile kalıcı veya geçici olarak 100x109/L altında olduğu bir hastalıktır. Selim hematolojik hastalıklar içinde yer almasına rağmen kanama komplikasyonları ölümcül olabilir. Hastalığın patofizyolojisi daha iyi anlaşılması ile son yıllarda kullanıma giren trombopoetin reseptör agonistleri, dirençli hastaların tedavisinde etkili bir seçenek olarak görünmektedir. Füsun Özdemirkıran, Bahriye Payzın, H. Demet Kiper, Sibel Kabukçu, Gülsüm Akgün Çağlıyan, Selda Kahraman, Ömür Gökmen Sevindik, Cengiz Ceylan, Gürhan Kadıköylü, Fahri Şahin, Ali Keskin, Öykü Arslan, Mehmet Ali Özcan, Gülnur Görgün, Zahit Bolaman, Filiz Büyükkeçeci, Oktay Bilgir, İnci Alacacıoğlu, Filiz Vural, Murat Tombuloğlu, Zafer Gökgöz, Güray Saydam. Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience. . 2015; 32(4): 323-328 Corresponding Author: Füsun Özdemirkıran, Türkiye |
|